胆舒胶囊联合头孢曲松治疗慢性胆囊炎的临床研究  

Clinical study of Danshu Capsules combined with ceftriaxone in treatment of chronic cholecystitis

作　　者：王云浩 丁春阳 方洋洋 徐秋旻 WANG Yun-hao;DING Chun-yang;FANG Yang-yang;XU Qiu-min(Department of Emergency Medicine,Nanjing Tongren Hospital Affiliated to Southeast University School of Medicine,Nanjing 211102,China)

机构地区：[1]东南大学医学院附属南京同仁医院急诊医学科,江苏南京211102

出　　处：《现代药物与临床》2023年第3期649-654,共6页Drugs & Clinic

摘　　要：目的探讨胆舒胶囊联合头孢曲松治疗慢性胆囊炎的临床疗效。方法选择2019年1月—2021年12月东南大学医学院附属南京同仁医院收治的148例慢性胆囊炎患者,按照随机数字表法分为对照组和治疗组,每组各74例。对照组给予注射用头孢曲松钠,每次将2 g加入0.9%氯化钠注射液250 mL中均匀混合后静脉滴注,1次/d。治疗组在对照组基础上口服胆舒胶囊,2粒/次,3次/d。两组疗程均为2周。观察两组的临床疗效,比较治疗前后两组主症积分、中医症状总积分、胃肠道生活质量指数(GIQLI)总分、胆囊壁厚度、胆囊收缩功能指标[胆囊空腹体积(GFV)、胆囊最小残余体积(MGRV)、胆囊最大排空率(MGER)]及血清肿瘤坏死因子(TNF)-α、白细胞介素(IL)-6、胆囊收缩素(CKK)、总胆汁酸(TBA)水平。结果治疗后,治疗组总有效率为94.59%,显著高于对照组的83.78%(P<0.05)。治疗后,两组主症积分、中医症状总积分均显著降低,GIQLI总分均显著升高(P<0.05);治疗后,治疗组主症积分、中医症状总积分、GIQLI总分改善均优于对照组(P<0.05)。治疗后,两组胆囊壁厚度、GFV、MGRV均较治疗前显著降低,MGER均显著升高(P<0.05),治疗后,治疗组胆囊壁厚度和胆囊收缩功能指标改善均优于对照组(P<0.05)。治疗后,两组血清TNF-α、IL-6、CCK、TBA水平均较治疗前显著降低(P<0.05);治疗后,治疗组血清TNF-α、IL-6、CCK、TBA水平均显著低于对照组(P<0.05)。结论胆舒胶囊联合头孢曲松治疗慢性胆囊炎疗效肯定,可缓解反复右上腹胀痛或不适等症状、改善胆囊功能及生活质量,并可进一步降低血清TNF-α、IL-6、CCK、TBA水平,值得临床推广应用。ObjectiveTo investigate the clinical efficacy of Danshu Capsulescombined with ceftriaxone in the treatment of chronic cholecystitis.MethodsA total of 148 patients with chronic cholecystitis admitted to Nanjing Tongren Hospital Affiliated to Southeast University School of Medicine from January 2019 to December 2021 were selected and divided into control group and treatment group according to random number table method,with 74 cases in each group.Patientsinthe control group were ivadministered with Ceftriaxone Sodium for Injection,2 g is added into 0.9%sodium chloride injection 250 mL each time and mix evenly before intravenous infusion,once daily.Patients in the treatmentgroup were poadministered withDanshu Capsuleson the basis of the control group,2grains/time,three times daily.Patientsin two groups were treated for 2weeks.After treatment,the clinicalefficacywas evaluated,the scores of main symptoms,the total score of TCM symptoms,the total score of gastrointestinal quality of life index(GIQLI),the thickness of the gallbladder wall,the index of gallbladder contraction function[gallbladder fasting volume(GFV),minimumresidual gallbladder volume(MGRV),maximum gallbladder emptying rate(MGER)],and serum tumor necrosis factor(TNF)-α,interleukin(IL)-6,cholecystokinin(CKK),total bile acid(TBA)levels in two groups before and after treatment were compared.ResultsAfter treatment,the total effective rate of the treatment group was 94.59%,significantly higher than that of the control group(83.78%)(P<0.05).After treatment,the main symptom score and total TCM symptom score were significantly decreased,and the total GIQLI score was significantly increased in both groups(P<0.05).After treatment,the improvement of main symptom score,TCM symptom score and GIQLI total score in the treatment group was better than that in the control group(P<0.05).After treatment,the thickness of gallbladder wall,GFV and MGRV of the two groups were significantly decreased,while the MGER was significantly increased(P<0.05).After treatment,the improvem

关 键 词：胆舒胶囊 注射用头孢曲松 慢性胆囊炎 胆囊收缩功能 炎症因子 总胆汁酸 

分 类 号：R975[医药卫生—药品]